Results 201 to 210 of about 44,865 (239)

Cerebellar Pleomorphic Xanthoastrocytoma with BRAF V600E Mutation

World Neurosurgery, 2020
Pleomorphic xanthoastrocytoma (PXA) is a rare type of astrocytoma with a peak incidence from 10 to 19 years of age. PXA is found most commonly in the supratentorium. When it is present in atypical areas such as the infratentorium, it is often overlooked as a potential differential diagnosis.This report discusses the case of an 18-year-old woman with a ...
Sang Ho Kim, Kihwan Hwang, Kyu Sang Lee, Gheeyoung Choe, Chae-Yong Kim   +4 more
openaire   +2 more sources

BRAF V600E Mutations in Endometrial Adenocarcinoma

Diagnostic Molecular Pathology, 2013
The BRAF V600E somatic mutation is recognized as an oncogenic driver of many human cancers involving the MAPK/ERK pathway. Colorectal and lung cancers associated with the BRAF V600E mutation often demonstrated mucinous morphology. This study hypothesized that the BRAF V600E mutation may be associated with mucinous morphology in endometrial cancer and ...
Mai, He, Virginia, Breese, Steven, Hang, Cunxian, Zhang, Jinjun, Xiong, Cynthia, Jackson   +5 more
openaire   +2 more sources

Histiocytose mixte, BRAF V600E mutée

La Revue de Médecine Interne, 2016
Introduction La maladie d’Erdheim-Chester (MEC) est une histiocytose non langerhansienne de l’adulte d’âge mur, associant osteosclerose symetrique des os longs, pseudo-fibrose retroperitoneale avec hydronephrose, infiltration peri-aortique et pericardique, exophtalmie, diabete insipide, atteinte cerebrale et cutanee type xanthelasma.
S. Parreau, J. Haroche, I. Pommepuy, J.F. Emile, F. Archambeaud   +4 more
openaire   +1 more source

BRAF V600E mutation-specific antibody: A review

Seminars in Diagnostic Pathology, 2015
The significance of BRAF mutations in neoplasia was first recognized in 2002 when mutations were discovered in a broad range of cancers. Numerous subsequent studies expanded our understanding of BRAF V600E as a critical diagnostic, prognostic, and predictive biomarker in many cancers.
Lauren L, Ritterhouse, Justine A, Barletta   +1 more
openaire   +2 more sources

Detection of BRAF V600E mutation by pyrosequencing

Pathology, 2008
Detection of the V600E hotspot mutation in BRAF oncogene is extremely useful for the screening of hereditary non-polyposis colorectal cancer (Lynch's syndrome) and for the prediction of sensitivity to MEK inhibitors. Here we describe a method for detecting this mutation based upon pyrosequencing technology.The efficiency of pyrosequencing for detecting
Tan, Y.H., Salto-Tellez, M., Soong, R., Liu, Y., Eu, K.W., Ang, P.W., Li, W.Q., Iacopetta, B.   +7 more
openaire   +3 more sources

BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma

Melanoma Research, 2016
Selective BRAF inhibitors (BRAFi) yield objective responses in 50% of patients with metastatic BRAF V600E mutant melanoma. Adding an MEK inhibitor increases this response rate to 70%. Limited data are available on the outcomes of unresectable stage III patients, and it remains unclear whether BRAF-targeted therapy can be utilized as a neoadjuvant ...
Sloot, Sarah, Zager, Jonathan S., Kudchadkar, Ragini R., Messina, Jane L., Benedict, Jacob J., Gonzalez, Ricardo J., DeConti, Ronald, Turner, Leslie M., McCardle, Timothy, Smalley, Keiran S. M., Weber, Jeffrey S., Sondak, Vernon K., Gibney, Geoffrey T.   +12 more
openaire   +3 more sources

Management of V600E and V600K BRAF-Mutant Melanoma

Current Treatment Options in Oncology, 2019
The optimal management of advanced stage BRAF-mutated melanoma is widely debated and complicated by the availability of several different regimens that significantly improve outcomes but have not been directly compared. While there are many unanswered questions relevant to this patient population, the major uncertainty in current practice is the choice
Alexandra M, Haugh, Douglas B, Johnson
openaire   +2 more sources

Dabrafenib in advanced melanoma with BRAF V600E mutation

The Journal of Community and Supportive Oncology, 2014
Dabrafenib was recently approved by the US Food and Drug Administration for treatment of unresectable or metastatic melanoma with BRAF V600E mutations as detected by an FDA-approved test. The THxID BRAF assay, for detection of BRAF V600E mutations was concurrently approved.
Jame, Abraham, Matt, Stenger
openaire   +2 more sources

?????????????????????? ???????????????? ???????????????????????? ?????? ???????????????? ???????? ?? ???????????????? BRAF V600E

2018
?? 40???60% ?????????????? ???????????????? ???????? ???????????????? ?????????????? ???????????????? BRAF, ???????????????????? ?????????????? ???????????????? ???????????????????????????? ?????????????????? ???????????????????????????????? ???????????? BRAF ??, ????????????????????????????, ?????????????????????? ?????????????? ???? ???????? MAPK/ERK.
Chapman, P.B., Hauschild, A., Robert, C.
openaire   +1 more source

Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas

Clinical Oral Investigations, 2018
This study aimed to investigate the presence of BRAF V600E mutation in mandible ameloblastomas by correlating clinical and imaging data on the cases studied.Eighty-four cases diagnosed as mandibular ameloblastoma were selected for analysis. The specimens were submitted to immunohistochemistry for detection of BRAF V600E mutated protein.
Alan Motta do Canto, Barbara Michaela Reis da Silva Marcelino, Juliana Lucena Schussel, Bruna F. Wastner, Laurindo Moacir Sassi, Luciana Corrêa, Ronaldo Rodrigues de Freitas, Bengt Hasséus, Göran Kjeller, Celso Augusto Lemos Junior, Paulo Henrique Braz-Silva   +10 more
openaire   +2 more sources